
The study evaluated the efficacy and safety of capivasertib, an AKT inhibitor, in combination with fulvestrant therapy for hormone receptor-positive advanced breast cancer patients. The capivasertib-fulvestrant combination therapy showed a median progression-free survival of 7.2 months compared to 3.6 months in the placebo-fulvestrant group. Among patients with AKT pathway alterations, the median progression-free survival was 7.3 months in the capivasertib-fulvestrant group compared to 3.1 months in the placebo-fulvestrant group. Adverse events such as rash and diarrhea were observed in the capivasertib group. These findings suggest that capivasertib, in combination with fulvestrant, extends progression-free survival in hormone receptor-positive advanced breast cancer patients, especially those with AKT pathway alterations.
Like
Save
Share